Diagnostik und Therapie der akuten myeloischen Leukämie

Schlüsselwörter

akute myeloische Leukämie - risikostratifizierte Therapie

Keywords

acute myeloid leukemia - risk-adapted therapy

Literatur

• 1 Bacher U, Badbaran A, Fehse B. et al . Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.  Exp Hematol. 2009;  37 135-142
• 2 Bennett J M, Catovsky D, Daniel M T. et al . Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.  Br J Haematol. 1976;  33 451-458
• 3 Buchner T, Hiddemann W, Wormann B. et al . Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.  Blood. 1999;  93 4116-4124
• 4 Cornelissen J J, van Putten W L, Verdonck L F. et al . Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?.  Blood. 2007;  109 3658-3666
• 5 Cornely O A, Maertens J, Winston D J. et al . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.  N Engl J Med. 2007;  356 348-359
• 6 Craig F E, Foon K A. Flow cytometric immunophenotyping for hematologic neoplasms.  Blood. 2008;  111 3941-3967
• 7 Hegenbart U, Niederwieser D, Sandmaier B M. et al . Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.  J Clin Oncol. 2006;  24 444-453
• 8 Marcucci G, Mrozek K, Ruppert A S. et al . Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.  J Clin Oncol. 2004;  22 2410-2418
• 9 Platzbecker U, Thiede C, Fussel M. et al . Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia.  Leukemia. 2006;  20 707-714
• 10 San Miguel J F, Martinez A, Macedo A. et al . Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.  Blood. 1997;  90 2465-2470
• 11 Schetelig J, Bornhauser M, Schmid C. et al . Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group.  J Clin Oncol. 2008;  26 5183-5191
• 12 Schlenk R F, Dohner K, Krauter J. et al . Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.  N Engl J Med. 2008;  358 1909-1918
• 13 Schmid C, Schleuning M, Schwerdtfeger R. et al . Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.  Blood. 2006;  108 1092-1099
• 14 Stelljes M, Bornhauser M, Kroger M. et al . Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.  Blood. 2005;  106 3314-3321
• 15 Thiede C, Steudel C, Mohr B. et al . Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.  Blood. 2002;  99 4326-4335
• 16 Vardiman J W, Thiele J, Arber D A. et al . The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes.  Blood. 2009;  114 937-951